Mark Copley, sales director for Copley Scientific, will discuss 'APSD and abbreviated impactor testing' at a one-day seminar focusing on the challenges of developing dry powder inhalers.
The seminar, on 8 November 2010, precedes the annual Management Forum conference on Inhaled Drug delivery, an international event that takes place on 8-9 November at Le Meridien Hotel, Piccadilly, London.
APSD - aerodynamic particle size distribution - measurement is mandated by the regulators for all inhaled products, because of the influence of particle size on in vivo behaviour.
Abbreviated impactor testing cuts the time taken to access defining size parameters.
Copley will explore the potential of abbreviated impactor measurements and efficient data analysis, to streamline and accelerate testing during development and quality control and, more generally, consider developments towards better in vitro/in vivo correlation
